Psoriasis Patients Rank Skin Clearance Highest
Early research suggests adults weighing systemic psoriasis treatments put skin clearance ahead of other features like how the drug is taken.
Updated on Nov. 4, 2026 in Diabetes
Live Poll
Would you accept a medication with more side effects if it cleared your skin faster?
Patients with moderate-to-severe psoriasis who are eligible for systemic treatment ranked skin clearance likelihood as the most influential factor in their choice of therapy, according to early results from a multicountry preference study presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada. The findings are relevant to people with psoriasis weighing biologic and oral options.
Why it matters
The number of systemic options for moderate to severe psoriasis keeps growing, so understanding which treatment attributes patients value most may help clinicians tailor shared decision-making as choices multiply. The study suggests that for many people, how well a treatment clears skin matters more than how it is taken.
This early-phase preference study enrolled 202 adults across the UK, US and Australia who met International Psoriasis Council criteria for systemic treatment, with a mean age of 44.8 years. Preferences were estimated with a multinomial logit model from repeated choices between hypothetical treatment profiles defined by seven attributes.
The details
Participants repeatedly chose between hypothetical treatment profiles, and the researchers used a multinomial logit model to convert those choices into relative attribute importance scores. Each score reflects how much weight a given feature carried in the decisions people made. In this initial phase, skin clearance at 52 weeks and at 16 weeks carried the most weight, while fasting requirements for oral therapy carried the least. Among the 43.5% of participants who had previously used a biologic and the 86.1% who had used an oral therapy, preferences were shaped by real treatment experience as well as hypothetical scenarios.
Timeline
Early results were presented at the 2026 Fall Clinical Dermatology Conference in Las Vegas, Nevada, on November 4, 2026.
Health Landscape
The growing number of systemic options for moderate-to-severe psoriasis has expanded comparative evidence across biologic and oral agents. This preference research adds a patient-centered layer to that evidence, showing how people weigh clearance, route of administration and side-effect risk when choosing among them.
If you have psoriasis and are discussing systemic treatment with your doctor, this research suggests that asking how a option is likely to clear your skin, and how it is taken, are central questions worth raising. Treatment preferences vary, so these population-level findings are best weighed alongside your own goals in a conversation with your physician.
The takeaway
Skin clearance and route of administration emerged as leading priorities in this early preference study, so these are useful themes to bring into a treatment conversation. Keep in mind that the full multicountry results are still pending and worth watching for.
Further reading
Explore more in the Diabetes section for related coverage of chronic conditions and treatment decision-making.
Source note: This article includes information reported by Hcplive.
Live Poll
Would you accept a medication with more side effects if it cleared your skin faster?
